Mr. Weinand is currently a member of the Board of Coya Therapeutics and Replimune, Chairman of the Board of Confo Therapeutics, and Executive Chairman of the Board of Mnemo Therapeutics.

US-based Dieter Weinand is the former CEO of Bayer Pharma with more than 25 years of experience as a senior business leader in the pharmaceutical industryThe appointment comes as AstriVax ...

Eli Lilly will buy privately held SiteOne Therapeutics in a deal worth as much as $1 billion, the companies said on Tuesday, giving the drugmaker access to an experimental non-opioid pain medicine.

In 2023, Lilly signed a deal with Confo Therapeutics to license its experimental non-opioid drug for neuropathic pain, a condition caused by damage to the nerves outside the brain and spinal cord.

Confo Therapeutics, a leader in the discovery of novel medicines targeting G-protein coupled receptors (GPCRs), today announced a publication in Nature Communications demonstrating the world’s ...

GHENT, Belgium, October 01, 2024--Confo Therapeutics, a leader in the discovery of novel medicines targeting G-protein coupled receptors (GPCRs), today announced a publication in Nature ...

Confo Therapeutics, a Belgian firm developing small molecules and antibodies that target G protein–coupled receptors, aims to start testing its drug candidates in humans with the help of $65 ...

Cardiometabolic disease —Confo Therapeutics, a developer of small molecules and antibodies that target G protein-coupled receptors, closed €60 million in financing.

GHENT, Belgium, July 26, 2024--Confo Therapeutics, a clinical-stage company and leader in the discovery of medicines targeting G-protein coupled receptors (GPCRs), today announced the closing of a ...

Profile The positions in the table below reflect the Confo Therapeutics's position overall, domestically, within their sector, and in various subject areas based on their Share. Each position ...